ArticleDigestive diseases and sciences2009
Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance.
Article in Digestive diseases and sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Context-dependent roles of resistin-like molecule β in mucosal defense and inflammatory diseases.Frontiers in immunology · 2026Review
- An Updated Review of Resistin and Colorectal Cancer.Cureus · 2024Review
- Evidence that the loss of colonic anti-microbial peptides may promote dysbiotic Gram-negative inflammaging-associated bacteria in aging mice.Frontiers in aging · 2024Article
- Resistin-like beta reduction is associated to low survival rate and is downregulated by adjuvant therapy in colorectal cancer patients.Scientific reports · 2023Article
- Resistin-like molecules: a marker, mediator and therapeutic target for multiple diseases.Cell communication and signaling : CCS · 2023Review
- The Mechanisms of Resistin-Like Molecule-β-Mediated Airway Inflammation in Chronic Obstructive Pulmonary Disease via Autophagy.Journal of inflammation research · 2023Article
- Diagnostic and Prognostic Roles of CDX2 Immunohistochemical Expression in Colorectal Cancers.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma.Head & face medicine · 2021Article
- The Role of Hypoxia-Induced Mitogenic Factor in Organ-Specific Inflammation in the Lung and Liver: Key Concepts and Gaps in Knowledge Regarding Molecular Mechanisms of Acute or Immune-Mediated Liver Injury.International journal of molecular sciences · 2021Review
- Helicobacter pylori Infection Facilitates the Expression of Resistin-like Molecule Beta in Gastric Carcinoma and Precursor Lesions.Current medical science · 2020Article
- Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer.Frontiers in oncology · 2020Article
- Role of Obesity in the Tumorigenesis of Gastric Cancer.International journal of preventive medicine · 2020Review
- Resistin-Like Molecule Beta (RELM-β) Regulates Proliferation of Human Diabetic Nephropathy Mesangial Cells via Mitogen-Activated Protein Kinases (MAPK) Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- A New Model to Study the Role of Arachidonic Acid in Colon Cancer Pathophysiology.Cancer prevention research (Philadelphia, Pa.) · 2016Article
- Pathological Type-2 Immune Response, Enhanced Tumor Growth, and Glucose Intolerance in Retnlβ (RELMβ) Null Mice: A Model of Intestinal Immune System Dysfunction in Disease Susceptibility.The American journal of pathology · 2016Article
- Resistin-Like Molecule-β Promotes Invasion and Migration of Gastric Carcinoma Cells.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Human resistin and the RELM of Inflammation in diabesity.Diabetology & metabolic syndrome · 2015Article
- Obesity and colorectal cancer: role of adipokines in tumor initiation and progression.World journal of gastroenterology · 2014Review
- Dynamic tumor growth patterns in a novel murine model of colorectal cancer.Cancer prevention research (Philadelphia, Pa.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have indicated that resistin-like molecule beta (RELM beta), an intestinal goblet cell-specific protein, is markedly increased in the intestinal tumors of min mice and over-expressed in a human colon cancer cell line. We hypothesized that RELM beta might be enhanced in human colon cancer. The aim of this study was to examine the clinical importance of RELM beta expression in colon cancer patients and to correlate its expression with various clinicopathological parameters, upstream regulatory molecule expression, tumor proliferative capacity, and patients' survival. Of the 80 colon cancer patients studied, 65 (81.25%) tested positive for RELM beta, mainly in the cytoplasm of colon mucosa. Contrasting sharply with the strongly RELM beta-positive tumors, normal colon mucous membrane was negative or weakly positive. RELM beta positivity in colon cancer was correlated with histological grade of differentiation and lymph node metastasis, but not with age, gender, tumor location and size, tumor infiltration, Dukes' stage, liver metastasis, and venous invasion. RELM beta expression was significantly correlated with the expression of transcription factor CDX-2 (P < 0.01) but not with that of proliferative index Ki-67 (P > 0.05). The mean postoperative survival time (2.76 years) of RELM beta-positive patients was significantly longer than that (1.26 years) of RELM beta-negative patients (P = 0.032). These findings support evidence of the enhanced RELM beta expression in colon cancer patients and suggest that further investigation is warranted to explore the role of RELM beta in colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.